Sarcopenia is associated with the risk of significant liver fibrosis in metabolically unhealthy subjects with chronic hepatitis B
Summary Background Sarcopenia is significantly associated with the degree of liver fibrosis. This study investigated the influence of sarcopenia on liver fibrosis in individuals with chronic hepatitis B. Methods Data from the Korean National Health and Nutrition Examination Surveys 2008‐2011 were an...
Saved in:
Published in | Alimentary pharmacology & therapeutics Vol. 48; no. 3; pp. 300 - 312 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Wiley Subscription Services, Inc
01.08.2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Summary
Background
Sarcopenia is significantly associated with the degree of liver fibrosis. This study investigated the influence of sarcopenia on liver fibrosis in individuals with chronic hepatitis B.
Methods
Data from the Korean National Health and Nutrition Examination Surveys 2008‐2011 were analysed. The sarcopenia index (total appendicular skeletal muscle mass [kg]/body mass index [kg/m2]) was calculated using dual‐energy X‐ray absorptiometry. Sarcopenia was defined as the lowest quintile sarcopenia index value (cut‐offs: 0.89 for men and 0.58 for women). The fibrotic burden was assessed using the nonalcoholic fatty liver disease fibrosis score and fibrosis‐4 index. Significant fibrosis was defined as the highest nonalcoholic fatty liver disease fibrosis score quartile and a fibrosis‐4 index ≥2.67.
Results
Among the 506 respondents with chronic hepatitis B (258 men and 248 women), the nonalcoholic fatty liver disease fibrosis score and fibrosis‐4 index identified sarcopenia and significant fibrosis in 126 (24.9%) and 217 (42.9%), respectively. Sarcopenia was significantly associated with significant fibrosis, regardless of the fibrosis prediction model used (all P < 0.05). When the study population was stratified according to metabolic factors, sarcopenia was specifically associated with an increased risk of significant fibrosis among subgroups with obesity, insulin resistance, metabolic syndrome and liver steatosis (odds ratio 2.37‐3.57; all P < 0.05). An independent association between sarcopenia and significant fibrosis was identified after adjusting for other confounders (odds ratio 2.67‐3.62 by the nonalcoholic fatty liver disease fibrosis score and 2.04‐2.62 by the fibrosis‐4 index; all P < 0.05).
Conclusions
Sarcopenia is associated with significant fibrosis in subjects with chronic hepatitis B, specifically those with obesity, insulin resistance, metabolic syndrome and liver steatosis.
Linked ContentThis article is linked to Mudaliar and Liu paper. To view this article visit https://doi.org/10.1111/apt.14894. |
---|---|
AbstractList | Linked Content
This article is linked to Mudaliar and Liu paper. To view this article visit
https://doi.org/10.1111/apt.14894
. BackgroundSarcopenia is significantly associated with the degree of liver fibrosis. This study investigated the influence of sarcopenia on liver fibrosis in individuals with chronic hepatitis B.MethodsData from the Korean National Health and Nutrition Examination Surveys 2008‐2011 were analysed. The sarcopenia index (total appendicular skeletal muscle mass [kg]/body mass index [kg/m2]) was calculated using dual‐energy X‐ray absorptiometry. Sarcopenia was defined as the lowest quintile sarcopenia index value (cut‐offs: 0.89 for men and 0.58 for women). The fibrotic burden was assessed using the nonalcoholic fatty liver disease fibrosis score and fibrosis‐4 index. Significant fibrosis was defined as the highest nonalcoholic fatty liver disease fibrosis score quartile and a fibrosis‐4 index ≥2.67.ResultsAmong the 506 respondents with chronic hepatitis B (258 men and 248 women), the nonalcoholic fatty liver disease fibrosis score and fibrosis‐4 index identified sarcopenia and significant fibrosis in 126 (24.9%) and 217 (42.9%), respectively. Sarcopenia was significantly associated with significant fibrosis, regardless of the fibrosis prediction model used (all P < 0.05). When the study population was stratified according to metabolic factors, sarcopenia was specifically associated with an increased risk of significant fibrosis among subgroups with obesity, insulin resistance, metabolic syndrome and liver steatosis (odds ratio 2.37‐3.57; all P < 0.05). An independent association between sarcopenia and significant fibrosis was identified after adjusting for other confounders (odds ratio 2.67‐3.62 by the nonalcoholic fatty liver disease fibrosis score and 2.04‐2.62 by the fibrosis‐4 index; all P < 0.05).ConclusionsSarcopenia is associated with significant fibrosis in subjects with chronic hepatitis B, specifically those with obesity, insulin resistance, metabolic syndrome and liver steatosis. Sarcopenia is significantly associated with the degree of liver fibrosis. This study investigated the influence of sarcopenia on liver fibrosis in individuals with chronic hepatitis B.BACKGROUNDSarcopenia is significantly associated with the degree of liver fibrosis. This study investigated the influence of sarcopenia on liver fibrosis in individuals with chronic hepatitis B.Data from the Korean National Health and Nutrition Examination Surveys 2008-2011 were analysed. The sarcopenia index (total appendicular skeletal muscle mass [kg]/body mass index [kg/m2 ]) was calculated using dual-energy X-ray absorptiometry. Sarcopenia was defined as the lowest quintile sarcopenia index value (cut-offs: 0.89 for men and 0.58 for women). The fibrotic burden was assessed using the nonalcoholic fatty liver disease fibrosis score and fibrosis-4 index. Significant fibrosis was defined as the highest nonalcoholic fatty liver disease fibrosis score quartile and a fibrosis-4 index ≥2.67.METHODSData from the Korean National Health and Nutrition Examination Surveys 2008-2011 were analysed. The sarcopenia index (total appendicular skeletal muscle mass [kg]/body mass index [kg/m2 ]) was calculated using dual-energy X-ray absorptiometry. Sarcopenia was defined as the lowest quintile sarcopenia index value (cut-offs: 0.89 for men and 0.58 for women). The fibrotic burden was assessed using the nonalcoholic fatty liver disease fibrosis score and fibrosis-4 index. Significant fibrosis was defined as the highest nonalcoholic fatty liver disease fibrosis score quartile and a fibrosis-4 index ≥2.67.Among the 506 respondents with chronic hepatitis B (258 men and 248 women), the nonalcoholic fatty liver disease fibrosis score and fibrosis-4 index identified sarcopenia and significant fibrosis in 126 (24.9%) and 217 (42.9%), respectively. Sarcopenia was significantly associated with significant fibrosis, regardless of the fibrosis prediction model used (all P < 0.05). When the study population was stratified according to metabolic factors, sarcopenia was specifically associated with an increased risk of significant fibrosis among subgroups with obesity, insulin resistance, metabolic syndrome and liver steatosis (odds ratio 2.37-3.57; all P < 0.05). An independent association between sarcopenia and significant fibrosis was identified after adjusting for other confounders (odds ratio 2.67-3.62 by the nonalcoholic fatty liver disease fibrosis score and 2.04-2.62 by the fibrosis-4 index; all P < 0.05).RESULTSAmong the 506 respondents with chronic hepatitis B (258 men and 248 women), the nonalcoholic fatty liver disease fibrosis score and fibrosis-4 index identified sarcopenia and significant fibrosis in 126 (24.9%) and 217 (42.9%), respectively. Sarcopenia was significantly associated with significant fibrosis, regardless of the fibrosis prediction model used (all P < 0.05). When the study population was stratified according to metabolic factors, sarcopenia was specifically associated with an increased risk of significant fibrosis among subgroups with obesity, insulin resistance, metabolic syndrome and liver steatosis (odds ratio 2.37-3.57; all P < 0.05). An independent association between sarcopenia and significant fibrosis was identified after adjusting for other confounders (odds ratio 2.67-3.62 by the nonalcoholic fatty liver disease fibrosis score and 2.04-2.62 by the fibrosis-4 index; all P < 0.05).Sarcopenia is associated with significant fibrosis in subjects with chronic hepatitis B, specifically those with obesity, insulin resistance, metabolic syndrome and liver steatosis.CONCLUSIONSSarcopenia is associated with significant fibrosis in subjects with chronic hepatitis B, specifically those with obesity, insulin resistance, metabolic syndrome and liver steatosis. Summary Background Sarcopenia is significantly associated with the degree of liver fibrosis. This study investigated the influence of sarcopenia on liver fibrosis in individuals with chronic hepatitis B. Methods Data from the Korean National Health and Nutrition Examination Surveys 2008‐2011 were analysed. The sarcopenia index (total appendicular skeletal muscle mass [kg]/body mass index [kg/m2]) was calculated using dual‐energy X‐ray absorptiometry. Sarcopenia was defined as the lowest quintile sarcopenia index value (cut‐offs: 0.89 for men and 0.58 for women). The fibrotic burden was assessed using the nonalcoholic fatty liver disease fibrosis score and fibrosis‐4 index. Significant fibrosis was defined as the highest nonalcoholic fatty liver disease fibrosis score quartile and a fibrosis‐4 index ≥2.67. Results Among the 506 respondents with chronic hepatitis B (258 men and 248 women), the nonalcoholic fatty liver disease fibrosis score and fibrosis‐4 index identified sarcopenia and significant fibrosis in 126 (24.9%) and 217 (42.9%), respectively. Sarcopenia was significantly associated with significant fibrosis, regardless of the fibrosis prediction model used (all P < 0.05). When the study population was stratified according to metabolic factors, sarcopenia was specifically associated with an increased risk of significant fibrosis among subgroups with obesity, insulin resistance, metabolic syndrome and liver steatosis (odds ratio 2.37‐3.57; all P < 0.05). An independent association between sarcopenia and significant fibrosis was identified after adjusting for other confounders (odds ratio 2.67‐3.62 by the nonalcoholic fatty liver disease fibrosis score and 2.04‐2.62 by the fibrosis‐4 index; all P < 0.05). Conclusions Sarcopenia is associated with significant fibrosis in subjects with chronic hepatitis B, specifically those with obesity, insulin resistance, metabolic syndrome and liver steatosis. Linked ContentThis article is linked to Mudaliar and Liu paper. To view this article visit https://doi.org/10.1111/apt.14894. Sarcopenia is significantly associated with the degree of liver fibrosis. This study investigated the influence of sarcopenia on liver fibrosis in individuals with chronic hepatitis B. Data from the Korean National Health and Nutrition Examination Surveys 2008-2011 were analysed. The sarcopenia index (total appendicular skeletal muscle mass [kg]/body mass index [kg/m ]) was calculated using dual-energy X-ray absorptiometry. Sarcopenia was defined as the lowest quintile sarcopenia index value (cut-offs: 0.89 for men and 0.58 for women). The fibrotic burden was assessed using the nonalcoholic fatty liver disease fibrosis score and fibrosis-4 index. Significant fibrosis was defined as the highest nonalcoholic fatty liver disease fibrosis score quartile and a fibrosis-4 index ≥2.67. Among the 506 respondents with chronic hepatitis B (258 men and 248 women), the nonalcoholic fatty liver disease fibrosis score and fibrosis-4 index identified sarcopenia and significant fibrosis in 126 (24.9%) and 217 (42.9%), respectively. Sarcopenia was significantly associated with significant fibrosis, regardless of the fibrosis prediction model used (all P < 0.05). When the study population was stratified according to metabolic factors, sarcopenia was specifically associated with an increased risk of significant fibrosis among subgroups with obesity, insulin resistance, metabolic syndrome and liver steatosis (odds ratio 2.37-3.57; all P < 0.05). An independent association between sarcopenia and significant fibrosis was identified after adjusting for other confounders (odds ratio 2.67-3.62 by the nonalcoholic fatty liver disease fibrosis score and 2.04-2.62 by the fibrosis-4 index; all P < 0.05). Sarcopenia is associated with significant fibrosis in subjects with chronic hepatitis B, specifically those with obesity, insulin resistance, metabolic syndrome and liver steatosis. |
Author | Kim, S. U. Lee, Y.‐h. Ahn, S. H. Han, K.‐H. Han, E. Park, J. Y. Lee, B.‐W. Cha, B.‐S. Kang, E. S. Kim, B. K. Kim, D. Y. |
Author_xml | – sequence: 1 givenname: E. orcidid: 0000-0002-3237-3317 surname: Han fullname: Han, E. organization: Keimyung University School of Medicine – sequence: 2 givenname: Y.‐h. orcidid: 0000-0002-6219-4942 surname: Lee fullname: Lee, Y.‐h. organization: Yonsei University College of Medicine – sequence: 3 givenname: B. K. surname: Kim fullname: Kim, B. K. organization: Yonsei University College of Medicine – sequence: 4 givenname: J. Y. surname: Park fullname: Park, J. Y. organization: Yonsei University College of Medicine – sequence: 5 givenname: D. Y. orcidid: 0000-0002-8327-3439 surname: Kim fullname: Kim, D. Y. organization: Yonsei University College of Medicine – sequence: 6 givenname: S. H. surname: Ahn fullname: Ahn, S. H. organization: Yonsei University College of Medicine – sequence: 7 givenname: B.‐W. surname: Lee fullname: Lee, B.‐W. organization: Yonsei University College of Medicine – sequence: 8 givenname: E. S. surname: Kang fullname: Kang, E. S. organization: Yonsei University College of Medicine – sequence: 9 givenname: B.‐S. surname: Cha fullname: Cha, B.‐S. organization: Yonsei University College of Medicine – sequence: 10 givenname: K.‐H. surname: Han fullname: Han, K.‐H. organization: Yonsei University College of Medicine – sequence: 11 givenname: S. U. orcidid: 0000-0002-9658-8050 surname: Kim fullname: Kim, S. U. email: ksukorea@yuhs.ac organization: Yonsei University College of Medicine |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29920701$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kc1u1DAURi1URKeFBS-ALLGBRVr_JE6ybCsKSJVAoqwtx3ND7uCxg-1QzZI3r8tMNxV4Y0s-35F9vxNy5IMHQl5zdsbLOjdzPuN1V8tnZMWlairBpDoiKyZUX4mOy2NyktKGMaZaJl6QY9H3grWMr8ifbybaMINHQzFRk1KwaDKs6R3mieYJaMT0k4aRJvzhcURrfKYOf0OkIw4xpBJDT7eQzRBcuXZuRxc_gXF52tG0DBuwOe19dorBo6UTzCZjLtHLl-T5aFyCV4f9lHy__nB79am6-fLx89XFTWVl18kK-rEe23Lua8bWUkjGm65Rta2NXDcgmehBGeBqkEKYQcmu7iSzkikF0FohT8m7vXeO4dcCKestJgvOGQ9hSVqwpq1rqZgq6Nsn6CYs0ZfXFUp1gnPVPgjfHKhl2MJazxG3Ju7043ALcL4HbJlSijBqi7l8O_gcDTrNmX6oT5f69N_6SuL9k8Sj9F_swX6HDnb_B_XF19t94h5O2KmV |
CitedBy_id | crossref_primary_10_3350_cmh_2023_0250 crossref_primary_10_1111_jgh_16261 crossref_primary_10_3390_ijms22041917 crossref_primary_10_1002_jcsm_12754 crossref_primary_10_1042_CS20180421 crossref_primary_10_1136_bmjopen_2022_066181 crossref_primary_10_4254_wjh_v14_i8_1652 crossref_primary_10_3390_biomedicines10010182 crossref_primary_10_3390_cancers13143424 crossref_primary_10_1038_s41598_019_48161_w crossref_primary_10_1080_17474124_2020_1757427 crossref_primary_10_1007_s10620_021_07157_1 crossref_primary_10_1016_j_dld_2020_07_004 crossref_primary_10_1097_MD_0000000000021038 crossref_primary_10_1111_apt_15026 crossref_primary_10_3390_diagnostics13071245 crossref_primary_10_1002_poh2_10 crossref_primary_10_1111_apt_14894 crossref_primary_10_1007_s11901_023_00596_6 crossref_primary_10_3390_life11020086 crossref_primary_10_1097_MEG_0000000000001475 crossref_primary_10_1038_s41598_020_72767_0 crossref_primary_10_1080_19932820_2023_2204564 crossref_primary_10_3892_br_2020_1273 crossref_primary_10_3390_life11040349 crossref_primary_10_5009_gnl220133 crossref_primary_10_1111_apt_17618 crossref_primary_10_5009_gnl19126 crossref_primary_10_1007_s11356_021_16202_5 crossref_primary_10_1186_s12944_021_01472_2 crossref_primary_10_1002_oby_23576 crossref_primary_10_5009_gnl19301 crossref_primary_10_1136_bmjopen_2019_034495 crossref_primary_10_4254_wjh_v15_i5_649 |
Cites_doi | 10.1093/gerona/glu010 10.1053/j.gastro.2008.02.001 10.1093/ije/dyt228 10.1002/lt.22472 10.1016/S0140-6736(12)61425-1 10.1002/hep.21669 10.1161/CIRCULATIONAHA.105.169404 10.1155/2017/2672435 10.1002/hep.28376 10.1210/jc.2013-3764 10.1053/j.gastro.2009.06.005 10.1111/jgh.13536 10.1507/endocrj.EJ17-0225 10.3350/cmh.2014.20.3.228 10.1038/nrgastro.2016.138 10.7326/0003-4819-150-9-200905050-00006 10.1007/s13539-012-0069-3 10.1007/BF00280883 10.4093/jkd.2014.15.2.76 10.1016/j.cgh.2016.05.039 10.1002/hep.21327 10.3851/IMP1982 10.1016/j.jhep.2015.02.051 10.1097/MEG.0000000000000661 10.1016/j.jhep.2016.07.040 10.2147/DDDT.S114761 10.1111/apt.13889 10.1016/j.jhep.2010.02.035 10.3748/wjg.v20.i2.475 10.1007/s13539-011-0035-5 10.1177/0884533612469027 10.1002/hep.23785 10.1136/gut.2008.157735 10.1186/1471-230X-6-33 10.1371/journal.pone.0107584 10.1111/jgh.12432 10.1111/jgh.12998 10.1097/MD.0000000000001682 10.4093/dmj.2011.35.6.561 10.1161/CIR.0b013e3181d0ba8b 10.1111/apt.13549 10.1007/s13539-011-0052-4 10.1053/jhep.2002.36128 10.1016/j.jhep.2016.08.019 |
ContentType | Journal Article |
Copyright | 2018 John Wiley & Sons Ltd 2018 John Wiley & Sons Ltd. Copyright © 2018 John Wiley & Sons Ltd |
Copyright_xml | – notice: 2018 John Wiley & Sons Ltd – notice: 2018 John Wiley & Sons Ltd. – notice: Copyright © 2018 John Wiley & Sons Ltd |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 7TK 7U9 H94 K9. M7N 7X8 |
DOI | 10.1111/apt.14843 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Neurosciences Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Algology Mycology and Protozoology Abstracts (Microbiology C) MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Virology and AIDS Abstracts Neurosciences Abstracts Algology Mycology and Protozoology Abstracts (Microbiology C) MEDLINE - Academic |
DatabaseTitleList | CrossRef AIDS and Cancer Research Abstracts MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1365-2036 |
EndPage | 312 |
ExternalDocumentID | 29920701 10_1111_apt_14843 APT14843 |
Genre | article Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | Republic of Korea |
GeographicLocations_xml | – name: Republic of Korea |
GrantInformation_xml | – fundername: Basic Science Research Program funderid: 2016R1A1A1A05005138; NRF‐2016R1A5A1010764 – fundername: National Research Foundation of Korea – fundername: Korea Healthcare Technology R&D Project funderid: HI17C0913 – fundername: Research of Korea Centers for Disease Control and Prevention funderid: 2016‐ER5103‐00; 2016‐ER5103‐01 |
GroupedDBID | --- .3N .GA .GJ .Y3 05W 0R~ 10A 1OB 1OC 23M 24P 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 6J9 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAKAS AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABOCM ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACUHS ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZCM ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AHEFC AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BAWUL BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF D-6 D-7 D-E D-F DC6 DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DTERQ E3Z EAD EAP EAS EBC EBD EBS EBX EJD EMB EMK EMOBN EST ESX EX3 F00 F01 F04 F5P FEDTE FIJ FUBAC FZ0 G-S G.N GODZA GX1 H.X HF~ HGLYW HVGLF HZI HZ~ IHE IPNFZ IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK0 MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D P6G PALCI Q.N Q11 QB0 Q~Q R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ SV3 TEORI TR2 TUS UB1 V8K V9Y W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR XG1 YOC ZZTAW ~IA ~WT AAYXX AGHNM AGQPQ AGYGG CITATION CGR CUY CVF ECM EIF NPM 7T5 7TK 7U9 AAMMB AEFGJ AGXDD AIDQK AIDYY H94 K9. M7N 7X8 |
ID | FETCH-LOGICAL-c3883-e9f4f7c389400d3230158564c4a3d5e3029e6ae16b322ab6384830c3066ee7c23 |
IEDL.DBID | DR2 |
ISSN | 0269-2813 1365-2036 |
IngestDate | Fri Jul 11 11:28:02 EDT 2025 Fri Jul 25 09:48:46 EDT 2025 Wed Feb 19 02:36:54 EST 2025 Thu Apr 24 23:02:21 EDT 2025 Tue Jul 01 02:22:23 EDT 2025 Wed Jan 22 17:05:47 EST 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Language | English |
License | 2018 John Wiley & Sons Ltd. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3883-e9f4f7c389400d3230158564c4a3d5e3029e6ae16b322ab6384830c3066ee7c23 |
Notes | Linked Content https://doi.org/10.1111/apt.14894 This article is linked to Mudaliar and Liu paper. To view this article visit . ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0002-3237-3317 0000-0002-9658-8050 0000-0002-8327-3439 0000-0002-6219-4942 |
OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/apt.14843 |
PMID | 29920701 |
PQID | 2068211672 |
PQPubID | 2045200 |
PageCount | 13 |
ParticipantIDs | proquest_miscellaneous_2057443606 proquest_journals_2068211672 pubmed_primary_29920701 crossref_citationtrail_10_1111_apt_14843 crossref_primary_10_1111_apt_14843 wiley_primary_10_1111_apt_14843_APT14843 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | August 2018 2018-08-00 20180801 |
PublicationDateYYYYMMDD | 2018-08-01 |
PublicationDate_xml | – month: 08 year: 2018 text: August 2018 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: Chichester |
PublicationTitle | Alimentary pharmacology & therapeutics |
PublicationTitleAlternate | Aliment Pharmacol Ther |
PublicationYear | 2018 |
Publisher | Wiley Subscription Services, Inc |
Publisher_xml | – name: Wiley Subscription Services, Inc |
References | 2002; 36 1985; 28 2017; 64 2010; 53 2011; 2 2013; 28 2017; 2017 2005; 112 2015; 94 2017; 66 2015; 30 2017; 45 2010; 121 2016; 10 2016; 32 2014; 69 2006; 6 2009; 150 2011; 35 2012; 18 2015; 13rd edition 2014; 29 2011; 16 2013; 381 2016; 14 2016; 13 2009; 137 2014; 43 2014; 20 2009; 58 2012; 3 2014; 2 2006; 44 2015; 63 2017; 32 2016; 43 2016; 65 2014; 15 2016; 63 2008; 134 2014; 9 2016; 28 2010; 52 2007; 46 2014; 99 e_1_2_7_5_1 e_1_2_7_4_1 e_1_2_7_3_1 e_1_2_7_9_1 e_1_2_7_8_1 e_1_2_7_7_1 Wu YJ (e_1_2_7_6_1) 2014; 2 e_1_2_7_19_1 e_1_2_7_18_1 Dasarathy S (e_1_2_7_41_1) 2016; 32 e_1_2_7_17_1 e_1_2_7_16_1 e_1_2_7_40_1 e_1_2_7_15_1 e_1_2_7_14_1 e_1_2_7_42_1 e_1_2_7_13_1 e_1_2_7_43_1 e_1_2_7_12_1 e_1_2_7_44_1 e_1_2_7_11_1 e_1_2_7_45_1 e_1_2_7_10_1 e_1_2_7_46_1 e_1_2_7_47_1 e_1_2_7_26_1 e_1_2_7_48_1 e_1_2_7_27_1 e_1_2_7_28_1 e_1_2_7_29_1 Hamborsky J KA (e_1_2_7_2_1) 2015 e_1_2_7_30_1 e_1_2_7_25_1 e_1_2_7_31_1 e_1_2_7_24_1 e_1_2_7_32_1 e_1_2_7_23_1 e_1_2_7_33_1 e_1_2_7_22_1 e_1_2_7_34_1 e_1_2_7_21_1 e_1_2_7_35_1 e_1_2_7_20_1 e_1_2_7_36_1 e_1_2_7_37_1 e_1_2_7_38_1 e_1_2_7_39_1 30156323 - Aliment Pharmacol Ther. 2018 Sep;48(5):579-580 |
References_xml | – volume: 381 start-page: 468 year: 2013 end-page: 475 article-title: Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5‐year open‐label follow‐up study publication-title: Lancet – volume: 66 start-page: 123 year: 2017 end-page: 131 article-title: Sarcopenia is an independent risk factor for non‐alcoholic steatohepatitis and significant fibrosis publication-title: J Hepatol – volume: 28 start-page: 412 year: 1985 end-page: 419 article-title: Homeostasis model assessment: insulin resistance and beta‐cell function from fasting plasma glucose and insulin concentrations in man publication-title: Diabetologia – volume: 29 start-page: 173 year: 2014 end-page: 178 article-title: Metabolic syndrome association with fibrosis development in chronic hepatitis B virus inactive carriers publication-title: J Gastroenterol Hepatol – volume: 52 start-page: 886 year: 2010 end-page: 893 article-title: Long‐term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B publication-title: Hepatology – volume: 28 start-page: 15 year: 2013 end-page: 29 article-title: Nutrition assessment and management in advanced liver disease publication-title: Nutr Clin Pract – volume: 14 start-page: 1647 year: 2016 end-page: 1656 article-title: Association between level of fibrosis, rather than antiviral regimen, and outcomes of patients with chronic hepatitis B publication-title: Clin Gastroenterol Hepatol – volume: 3 start-page: 225 year: 2012 end-page: 237 article-title: Consilience in sarcopenia of cirrhosis publication-title: J Cachexia Sarcopenia Muscle – volume: 10 start-page: 2739 year: 2016 end-page: 2744 article-title: The effects of the insulin resistance index on the virologic response to entecavir in patients with HBeAg‐positive chronic hepatitis B and nonalcoholic fatty liver disease publication-title: Drug Des Devel Ther – volume: 69 start-page: 547 year: 2014 end-page: 558 article-title: The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates publication-title: J Gerontol A Biol Sci Med Sci – volume: 15 start-page: 76 year: 2014 end-page: 81 article-title: Causal relationship of non‐alcoholic fatty liver disease with obesity and insulin resistance publication-title: J Korean Diabetes – volume: 63 start-page: 486 year: 2015 end-page: 493 article-title: Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008‐2011) publication-title: J Hepatol – volume: 2 start-page: 143 year: 2011 end-page: 151 article-title: The role of myostatin in muscle wasting: an overview publication-title: J Cachexia Sarcopenia Muscle – volume: 137 start-page: 865 year: 2009 end-page: 872 article-title: Prediction of non‐alcoholic fatty liver disease and liver fat using metabolic and genetic factors publication-title: Gastroenterology – volume: 3 start-page: 77 year: 2012 end-page: 94 article-title: Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass publication-title: J Cachexia Sarcopenia Muscle – volume: 43 start-page: 765 year: 2016 end-page: 777 article-title: Review article: sarcopenia in cirrhosis–aetiology, implications and potential therapeutic interventions publication-title: Aliment Pharmacol Ther – volume: 46 start-page: 32 year: 2007 end-page: 36 article-title: FIB‐4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest publication-title: Hepatology – volume: 53 start-page: 348 year: 2010 end-page: 356 article-title: Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review publication-title: J Hepatol – volume: 35 start-page: 561 year: 2011 end-page: 566 article-title: Obesity and metabolic syndrome in Korea publication-title: Diabetes Metab J – volume: 2 start-page: 222 year: 2014 end-page: 227 article-title: Clinical advances in fibrosis progression of chronic hepatitis B and C publication-title: J Clin Transl Hepatol – volume: 44 start-page: 865 year: 2006 end-page: 873 article-title: Long‐term follow‐up of patients with NAFLD and elevated liver enzymes publication-title: Hepatology – volume: 13rd edition year: 2015 – volume: 58 start-page: 111 year: 2009 end-page: 117 article-title: Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B publication-title: Gut – volume: 150 start-page: 604 year: 2009 end-page: 612 article-title: A new equation to estimate glomerular filtration rate publication-title: Ann Intern Med – volume: 20 start-page: 228 year: 2014 end-page: 236 article-title: Prediction of fibrosis progression in chronic viral hepatitis publication-title: Clin Mol Hepatol – volume: 13 start-page: 643 year: 2016 end-page: 653 article-title: Screening and diagnosis of HBV in low‐income and middle‐income countries publication-title: Nat Rev Gastroenterol Hepatol – volume: 9 start-page: e107584 year: 2014 article-title: Non‐laboratory‐based self‐assessment screening score for non‐alcoholic fatty liver disease: development, validation and comparison with other scores publication-title: PLoS ONE – volume: 43 start-page: 69 year: 2014 end-page: 77 article-title: Data resource profile: the Korea National Health and Nutrition Examination Survey (KNHANES) publication-title: Int J Epidemiol – volume: 28 start-page: 940 year: 2016 end-page: 947 article-title: Sarcopenia and two types of presarcopenia in Japanese patients with chronic liver disease publication-title: Eur J Gastroenterol Hepatol – volume: 134 start-page: 1729 year: 2008 end-page: 1740 article-title: Nutrition in end‐stage liver disease: principles and practice publication-title: Gastroenterology – volume: 65 start-page: 1232 year: 2016 end-page: 1244 article-title: Sarcopenia from mechanism to diagnosis and treatment in liver disease publication-title: J Hepatol – volume: 45 start-page: 510 year: 2017 end-page: 518 article-title: Sarcopenia is associated with severe liver fibrosis in patients with non‐alcoholic fatty liver disease publication-title: Aliment Pharmacol Ther – volume: 30 start-page: 1753 year: 2015 end-page: 1758 article-title: Thyroid function is associated with non‐alcoholic fatty liver disease in chronic hepatitis B‐infected subjects publication-title: J Gastroenterol Hepatol – volume: 6 start-page: 33 year: 2006 article-title: The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population publication-title: BMC Gastroenterol – volume: 2017 start-page: 2672435 year: 2017 article-title: Exercise and protein intake: a synergistic approach against Sarcopenia publication-title: Biomed Res Int – volume: 36 start-page: 986 year: 2002 end-page: 992 article-title: Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model publication-title: Hepatology – volume: 121 start-page: 354 year: 2010 end-page: 356 article-title: Myostatin: regulator of muscle wasting in heart failure and treatment target for cardiac cachexia publication-title: Circulation – volume: 63 start-page: 776 year: 2016 end-page: 786 article-title: Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008‐2011) publication-title: Hepatology – volume: 94 start-page: e1682 year: 2015 article-title: Validation of the fatty liver index for nonalcoholic fatty liver disease in middle‐aged and elderly Chinese publication-title: Medicine (Baltimore) – volume: 32 start-page: 159 year: 2016 end-page: 165 article-title: Cause and management of muscle wasting in chronic liver disease publication-title: Curr Opin Gastroenterol – volume: 64 start-page: 1137 year: 2017 end-page: 1142 article-title: Free testosterone concentration is inversely associated with markers of liver fibrosis in men with type 2 diabetes mellitus publication-title: Endocr J – volume: 99 start-page: 3879 year: 2014 end-page: 3888 article-title: The combination of vitamin D deficiency and mild to moderate chronic kidney disease is associated with low bone mineral density and deteriorated femoral microarchitecture: results from the KNHANES 2008‐2011 publication-title: J Clin Endocrinol Metab – volume: 112 start-page: 2735 year: 2005 end-page: 2752 article-title: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement publication-title: Circulation – volume: 32 start-page: 667 year: 2017 end-page: 676 article-title: Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B publication-title: J Gastroenterol Hepatol – volume: 16 start-page: 1169 year: 2011 end-page: 1186 article-title: HBV genotypes: relevance to natural history, pathogenesis and treatment of chronic hepatitis B publication-title: Antivir Ther – volume: 20 start-page: 475 year: 2014 end-page: 485 article-title: Limitations of liver biopsy and non‐invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis publication-title: World J Gastroenterol – volume: 18 start-page: 146 year: 2012 end-page: 151 article-title: Exercise capacity and muscle strength in patients with cirrhosis publication-title: Liver Transpl – ident: e_1_2_7_17_1 doi: 10.1093/gerona/glu010 – ident: e_1_2_7_10_1 doi: 10.1053/j.gastro.2008.02.001 – ident: e_1_2_7_16_1 doi: 10.1093/ije/dyt228 – ident: e_1_2_7_42_1 doi: 10.1002/lt.22472 – volume: 2 start-page: 222 year: 2014 ident: e_1_2_7_6_1 article-title: Clinical advances in fibrosis progression of chronic hepatitis B and C publication-title: J Clin Transl Hepatol – ident: e_1_2_7_7_1 doi: 10.1016/S0140-6736(12)61425-1 – ident: e_1_2_7_21_1 doi: 10.1002/hep.21669 – ident: e_1_2_7_29_1 doi: 10.1161/CIRCULATIONAHA.105.169404 – ident: e_1_2_7_30_1 doi: 10.1155/2017/2672435 – ident: e_1_2_7_14_1 doi: 10.1002/hep.28376 – ident: e_1_2_7_18_1 doi: 10.1210/jc.2013-3764 – ident: e_1_2_7_20_1 doi: 10.1053/j.gastro.2009.06.005 – ident: e_1_2_7_35_1 doi: 10.1111/jgh.13536 – volume: 32 start-page: 159 year: 2016 ident: e_1_2_7_41_1 article-title: Cause and management of muscle wasting in chronic liver disease publication-title: Curr Opin Gastroenterol – ident: e_1_2_7_47_1 doi: 10.1507/endocrj.EJ17-0225 – ident: e_1_2_7_5_1 doi: 10.3350/cmh.2014.20.3.228 – ident: e_1_2_7_3_1 doi: 10.1038/nrgastro.2016.138 – volume-title: Epidemiology and Prevention of Vaccine‐Preventable Diseases year: 2015 ident: e_1_2_7_2_1 – ident: e_1_2_7_19_1 doi: 10.7326/0003-4819-150-9-200905050-00006 – ident: e_1_2_7_9_1 doi: 10.1007/s13539-012-0069-3 – ident: e_1_2_7_28_1 doi: 10.1007/BF00280883 – ident: e_1_2_7_38_1 doi: 10.4093/jkd.2014.15.2.76 – ident: e_1_2_7_32_1 doi: 10.1016/j.cgh.2016.05.039 – ident: e_1_2_7_33_1 doi: 10.1002/hep.21327 – ident: e_1_2_7_4_1 doi: 10.3851/IMP1982 – ident: e_1_2_7_13_1 doi: 10.1016/j.jhep.2015.02.051 – ident: e_1_2_7_31_1 doi: 10.1097/MEG.0000000000000661 – ident: e_1_2_7_43_1 doi: 10.1016/j.jhep.2016.07.040 – ident: e_1_2_7_39_1 doi: 10.2147/DDDT.S114761 – ident: e_1_2_7_45_1 doi: 10.1111/apt.13889 – ident: e_1_2_7_34_1 doi: 10.1016/j.jhep.2010.02.035 – ident: e_1_2_7_26_1 doi: 10.3748/wjg.v20.i2.475 – ident: e_1_2_7_11_1 doi: 10.1007/s13539-011-0035-5 – ident: e_1_2_7_48_1 doi: 10.1177/0884533612469027 – ident: e_1_2_7_8_1 doi: 10.1002/hep.23785 – ident: e_1_2_7_36_1 doi: 10.1136/gut.2008.157735 – ident: e_1_2_7_24_1 doi: 10.1186/1471-230X-6-33 – ident: e_1_2_7_25_1 doi: 10.1371/journal.pone.0107584 – ident: e_1_2_7_44_1 doi: 10.1111/jgh.12432 – ident: e_1_2_7_46_1 doi: 10.1111/jgh.12998 – ident: e_1_2_7_23_1 doi: 10.1097/MD.0000000000001682 – ident: e_1_2_7_27_1 doi: 10.4093/dmj.2011.35.6.561 – ident: e_1_2_7_12_1 doi: 10.1161/CIR.0b013e3181d0ba8b – ident: e_1_2_7_37_1 doi: 10.1111/apt.13549 – ident: e_1_2_7_40_1 doi: 10.1007/s13539-011-0052-4 – ident: e_1_2_7_22_1 doi: 10.1053/jhep.2002.36128 – ident: e_1_2_7_15_1 doi: 10.1016/j.jhep.2016.08.019 – reference: 30156323 - Aliment Pharmacol Ther. 2018 Sep;48(5):579-580 |
SSID | ssj0006702 |
Score | 2.420683 |
Snippet | Summary
Background
Sarcopenia is significantly associated with the degree of liver fibrosis. This study investigated the influence of sarcopenia on liver... Linked Content This article is linked to Mudaliar and Liu paper. To view this article visit https://doi.org/10.1111/apt.14894 . Sarcopenia is significantly associated with the degree of liver fibrosis. This study investigated the influence of sarcopenia on liver fibrosis in individuals... BackgroundSarcopenia is significantly associated with the degree of liver fibrosis. This study investigated the influence of sarcopenia on liver fibrosis in... |
SourceID | proquest pubmed crossref wiley |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 300 |
SubjectTerms | Absorptiometry, Photon Adult Aged Body Mass Index Cross-Sectional Studies Fatty liver Female Fibrosis Hepatitis Hepatitis B Hepatitis B, Chronic - complications Hepatitis B, Chronic - epidemiology Humans Insulin Insulin Resistance Liver Cirrhosis - complications Liver Cirrhosis - epidemiology Liver diseases Male Metabolic Diseases - complications Metabolic Diseases - epidemiology Metabolic syndrome Metabolic Syndrome - complications Metabolic Syndrome - epidemiology Middle Aged Non-alcoholic Fatty Liver Disease - complications Non-alcoholic Fatty Liver Disease - epidemiology Nutrition Surveys Obesity Obesity - complications Obesity - epidemiology Population studies Republic of Korea - epidemiology Risk Factors Sarcopenia Sarcopenia - complications Sarcopenia - diagnosis Sarcopenia - epidemiology Skeletal muscle Steatosis |
Title | Sarcopenia is associated with the risk of significant liver fibrosis in metabolically unhealthy subjects with chronic hepatitis B |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fapt.14843 https://www.ncbi.nlm.nih.gov/pubmed/29920701 https://www.proquest.com/docview/2068211672 https://www.proquest.com/docview/2057443606 |
Volume | 48 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dS-QwEB9EQe5FvQ91PU_i4cO9VNImzab4tHt3iwiK-AE-HJS0m-Li2hXbPujb_efONG3VU-HwLdCkTTPzy8wkv0wAdjIusyhMAg-tW-hJnXGcByPj2TA0WuiQW8e2OFL75_LgIryYg732LIzLD9EtuBEy6vmaAG6S4gnIzU2JMNeSMn0SV4scopPH1FGqX_MNMcSIvED7oskqRCyeruVzW_TCwXzur9YGZ7QMf9quOp7J1W5VJrvp_T9ZHN_5Lyuw1DiibOA05yPM2fwTLB42W-2f4e8pQoDu1poYNimYacRox4yWbhn6jYxo6WyWMeKAEOMIhcSmxPNgGfZmVmCzSc6ubYmKRmuD0-kdq3J38vKOFVVCa0CFe1_qkvSyS0sU7xKbDr_A-ej32c99r7mvwUuF1sKzUSazPpbpsvWxwODGRwVQMpVGjEMreBBZZayvEpxFTILIl1rwFIMWZW0_DcQqzOez3K4D09JHz0Ja1J1IKm60HBuj0JIqjtE8z3rwo5VcnDbJzOlOjWncBjU4pHE9pD343lW9cRk8Xqu02Yo_bkBcxAFXOqB9qqAH291jhB_tqZjcziqqE_alFBgG9mDNqU33FbT0AXbWx87Wwn_78_Hg-KwubPx_1a_wAZ037ciImzBf3lb2GzpIZbIFC4Phr-Foq0bEA58oDCw |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB5RkAqXlvLclrYu6oFLkBM7XkfiQlvQtgVUwSJxQZGTdcSKJYua5EBv_PPOxEkoFKSqt0hrb5zMfJ6Hv8wAfMy4zKIwCTy0bqEndcZxH4yMZ8PQaKFDbh3b4kgNTuW3s_BsBnbab2FcfYgu4UbIqPdrAjglpP9AubkuEedaimcwRx29qXL-l-O74lGqXzMOMciIvED7oqkrRDyebup9a_SXi3nfY61Nzv5LOG8X65gml9tVmWynvx7Ucfzfp1mEF40vynad8ryCGZsvwfPD5rR9GW5PEAXUXmts2LhgppGkHTHK3jJ0HRkx09k0Y0QDIdIRyolNiOrBMlzOtMBp45xd2RJ1jdKDk8kNq3L38eUNK6qE0kCF-7_U1ellF5ZY3iVO_bQCp_t7w88Dr2nZ4KVCa-HZKJNZH6-p3_pIYHzjow4omUojRqEVPIisMtZXCW4kJkHwSy14inGLsrafBmIVZvNpbteBaemjcyEtqk8kFTdajoxRaEwVx4CeZz3YakUXp009c2qrMYnbuAZfaVy_0h5sdkOvXRGPxwZttPKPGxwXccCVDuioKujBh-5nRCAdq5jcTisaE_alFBgJ9mDN6U13FzT2AS7Wx8XW0n_69vHuj2F98frfh76H-cHw8CA--Hr0_Q0soC-nHTdxA2bLn5V9i_5SmbyrYfEb45AO1g |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3PT9VAEJ4AJoSLoCg-RFmNBy4lbXe73YYTii-ASgg_Eg4mzbbdjS8--15se8Cb_7kz3baKSkK4Neluu92Zb2dm9-sMwBvrC5tEWeihdYs8oayP62CiPRNFWnEV-caxLU7k4aU4voquFmCv_xfG5YcYNtwIGe16TQCfF_YPkOt5jTBXgi_CAyH9hOo2HJz9zh0l45ZwiDFG4oUq4F1aIaLxDF1vGqN_PMybDmtrccar8LkfqyOafN1t6mw3__FXGsd7fswaPOw8UbbvVOcRLJjyMSx_6s7a1-HnOWKAimtNNJtUTHdyNAWjvVuGjiMjXjqbWUYkEKIcoZTYlIgezOJoZhV2m5Tsm6lR02hzcDq9Zk3pfr28ZlWT0SZQ5Z6Xuyy97IshjneNXd8-gcvx-4t3h15XsMHLuVLcM4kVNsZrqrZecIxuAtQAKXKheREZ7oeJkdoEMsNlRGcIfaG4n2PUIo2J85A_haVyVppnwJQI0LUQBpUnQelqJQqtJZpSknTs2xHs9JJL8y6bORXVmKZ9VINTmrZTOoLXQ9O5S-Hxv0ZbvfjTDsVVGvpShXRQFY7g1XAb8UeHKro0s4baRLEQHOPAEWw4tRnegqY-xMEGONhW-Le_Pt0_vWgvNu_edBuWTw_G6cejkw_PYQUdOeWIiVuwVH9vzAt0lursZQuKX64hDYU |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Sarcopenia+is+associated+with+the+risk+of+significant+liver+fibrosis+in+metabolically+unhealthy+subjects+with+chronic+hepatitis+B&rft.jtitle=Alimentary+pharmacology+%26+therapeutics&rft.au=Han%2C+E&rft.au=Lee%2C+Y-H&rft.au=Kim%2C+B+K&rft.au=Park%2C+J+Y&rft.date=2018-08-01&rft.eissn=1365-2036&rft.volume=48&rft.issue=3&rft.spage=300&rft_id=info:doi/10.1111%2Fapt.14843&rft_id=info%3Apmid%2F29920701&rft.externalDocID=29920701 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0269-2813&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0269-2813&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0269-2813&client=summon |